Graphite Bio, Inc.

CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversif

Investor interest in biopharmaceutical opportunities is slowly but surely improving in 2024, including both private investors and public-sector funders of drug development infrastructure. In mid-month

Biogen, Inc. has been on the hunt during the past few years for outside assets that can help diversify its largely neurology-focused portfolio, and CEO Chris Viehbacher has been adamant that the comp

Biogen, Inc. has been no stranger to the biopharma spotlight during the past few years, but behind the scrutiny of the company’s Alzheimer’s drug approvals and its need to return to revenue growth, h